Immunotherapy in the treatment of lymphoma

doi:10.4252/wjsc.v13.i6.503

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5280)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

285

WORD

123

HTML

2985

Tables (1-5)

316

Sum=3709

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

534

Download

1033

Sum=1567

Jun 26, 2021 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Jun 26, 2021; 13(6): 503-520
Published online Jun 26, 2021. doi: 10.4252/wjsc.v13.i6.503

Table 3 Bispecific antibody studies

Drug	Target	No. of patients	Study design	Study phase	Results
Blinatumomab[71]	CD3/CD19	38	R/R FL, MCL, DLBCL	1	ORR/CR: 64%/38%; PFS 6.7 mo; OS 4.6 yr; OS ( for CR/PR): 7.7 yr; AEs: Infections (pneumonia, diarrhea, sepsis)
Mosunetuzumab[72]	CD3/CD20	218	R/R B-NHL	1	NHL ORR/CR: 64.1%/42.2%; DLBCL ORR/CR: 34.7%/16.6% AEs: CRS 28.4%, NAEs: 44%
CD20-TCB[73]	CD3/CD20	38	R/R DLBCL	1	ORR/CR: 47%/34% AEs: CRS 55.1%, Neutropenia 34.7%

AE: Adverse event; CR: Complete response; CRS: Cytokine releasing syndrome; DLBCL: Diffuse large B-Cell lymphoma; FL: Follicular lymphoma; MCL: Mantle cell lymphoma; NHL: Non-Hodgkin lymphoma; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; R/R: Relapsed/refractory.

Citation: Popovic LS, Matovina-Brko G, Popovic M, Popovic M, Cvetanovic A, Nikolic I, Kukic B, Petrovic D. Immunotherapy in the treatment of lymphoma. World J Stem Cells 2021; 13(6): 503-520
URL: https://www.wjgnet.com/1948-0210/full/v13/i6/503.htm
DOI: https://dx.doi.org/10.4252/wjsc.v13.i6.503